Guardant Health Expects Improved Guardant360 Liquid CDx Reimbursement in 2027
Bitget2026/11/05 23:30- Guardant Health expects about 30% full-year 2026 growth for Guardant360 Liquid, fueled by its Smart Platform.
- Third-quarter oncology revenue rose 25% to $231 million; testing volume increased 58% to 117,000.
- Improved reimbursement for Guardant360 Liquid CDx remains on track for 2027, with ADLT designation expected in the first half.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WLFI: Token buyback will be carried out on Aster through a public wallet
Layer 33 calls for a pause on removing validators under the new Solana Foundation regulations
HIVE’s Bitcoin output jumps 49%, but mining revenue still falls
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Crypto prices
More
